Evidence map›Paper›PMID 33973186›Full record

ArticleAdvances in experimental medicine and biology2021

COVID-19 in Patients with Cancer.

Ali Nowroozi, Sepideh Razi, Kamal Kant Sahu, Fabio Grizzi, Jann Arends, Mahsa Keshavarz-Fathi, Nima Rezaei

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ali NowrooziCancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Sepideh RaziCancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran. sepidrazi1994@gmail.com.
Kamal Kant SahuDepartment of Medicine, Saint Vincent Hospital, Worcester, MA, USA.
Fabio GrizziDepartment of Immunology and Inflammation, Humanitas Clinical and Research Center, Milan, Italy.
Jann ArendsDepartment of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Mahsa Keshavarz-FathiCancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Nima RezaeiResearch Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran. rezaei_nima@tums.ac.ir.ORCID https://orcid.org/0000-0002-3836-1827

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With more than 5 million cases and 333,212 deaths, COVID-19 (or SARS-CoV-2) continues to spread. General symptoms of this disease are similar to that of many other viral respiratory diseases, including fever, cough, dyspnea, and fatigue, with a chance of progression to more severe complications. However, the virus does not affect all people equally, and cases with comorbidities such as malignancies, cardiovascular diseases, respiratory diseases, and kidney diseases are at higher risk of developing severe events, including requiring intensive ventilation, intensive care unit (ICU) admission, and death. Patients with cancer are more likely to be infected with COVID-19, which is possibly due to their immunological dysfunction or frequent clinic visits. Also, there is a higher chance that these patients experience severe events because of the medication they receive. In this chapter, we will review the main clinical manifestations of COVID-19 in patients with cancer. Recommendations and challenges for managing resources, organizing cancer centers, treatment of COVID-19-infected cancer patients, and performing cancer research during this pandemic will also be discussed.

Indexed as

COVID-19NeoplasmsCoughHumansPandemicsSARS-CoV-2CancerCOVID-19MalignancyNeoplasmPandemicSARS-CoV-2

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.